A
Andrew M. Campbell
Researcher at Thermo Fisher Scientific
Publications - 5
Citations - 186
Andrew M. Campbell is an academic researcher from Thermo Fisher Scientific. The author has contributed to research in topics: Fluxomics & Varicella zoster virus. The author has an hindex of 3, co-authored 5 publications receiving 143 citations.
Papers
More filters
Journal ArticleDOI
Concise Review: Process Development Considerations for Cell Therapy
Andrew M. Campbell,Thomas Brieva,Lior Raviv,Jon A. Rowley,Knut Niss,Harvey Brandwein,Steve Oh,Ohad Karnieli +7 more
TL;DR: The goal is to identify potential manufacturing concerns early in the process so they may be addressed effectively and thus increase the probability that a therapy will be successful, and to identify the basic questions that affect process development.
Journal ArticleDOI
CHO-Omics Review: The Impact of Current and Emerging Technologies on Chinese Hamster Ovary Based Bioproduction
Gino Stolfa,Matthew T. Smonskey,Ryan Boniface,Anna-Barbara Hachmann,Paul Gulde,Atul D. Joshi,Anson Pierce,Scott J. Jacobia,Andrew M. Campbell +8 more
TL;DR: While individual omics technologies provide incremental improvements in bioproduction, the authors will likely see the most significant gains by applying multi‐omics and systems biology approaches to individual CHO cell lines.
Journal ArticleDOI
Optimization of bioprocess conditions improves production of a CHO cell-derived, bioengineered heparin
Jong Youn Baik,Hussain Dahodwala,Eziafa I. Oduah,Lee Talman,Trent R. Gemmill,Trent R. Gemmill,Leyla Gasimli,Payel Datta,Bo Yang,Guoyun Li,Fuming Zhang,Lingyun Li,Robert J. Linhardt,Andrew M. Campbell,Stephen F. Gorfien,Susan T. Sharfstein +15 more
TL;DR: Bioprocess optimization, in parallel with metabolic engineering refinements, will play a substantial role in developing a bioengineered heparin to replace the current animal-derived drug.